Descrizione del progetto
Uno strumento di imaging più sicuro per i vasi sanguigni
La diagnosi e il monitoraggio delle malattie cardiovascolari prevedono l’imaging radiografico dei vasi sanguigni con un metodo noto come angiografia. Questa tecnica può tuttavia avere effetti collaterali dannosi, quali il cancro indotto dalle radiazioni, sia sul paziente che sul personale che svolge la procedura. Inoltre, i pazienti affrontano il rischio di potenziale lesione renale. Il progetto KMIT-ACC, finanziato dall’UE, ha sviluppato una nuova tecnologia di imaging angiografico che contiene la dose di raggi X e i mezzi di contrasto a base di iodio, offrendo nel contempo una migliore qualità dell’immagine. L’adozione della gestione delle dosi di KMIT-ACC e dello strumento di elaborazione delle immagini in ambito clinico dovrebbe ridurre l’impatto negativo dell’angiografia convenzionale e apportare significativi benefici socioeconomici.
Obiettivo
Cardiovascular disorders are the number one health problem in the high-income societies. X-ray imaging of blood vessels is widely used in diagnosis and treatment of cardiovascular conditions, but it has several drawbacks: Image quality is sometimes insufficient; Applied Iodinated Contrast Media (ICM) may induce kidney injuries; X-ray exposure of patient and staff may cause cancer. Image quality improvement and radical reduction of ICM/X-ray dose are an unmet need. Our team has developed Digital Variance Angiography imaging and implemented it in a software, the Kinepict Medical Imaging Tool (KMIT). This ground-breaking patented technology can change the currently used angiography methods, improving image quality (3-10 times higher signal-to-noise ratio) and providing a dose management solution to reduce X-ray and ICM dose at least by 75% and 50%, respectively. Using the KMIT offers several advantages: a)Risk of angiography procedures is reduced dramatically for both patient and staff. b)The society benefits from smaller morbidity and mortality of cancer and kidney injury c)Hospitals save 220,000 €/year on direct costs d)Health care system expenses are reduced by around 300,000 €/year/licencing hospital e)Total savings might reach the 300 M€/year in the EU (assuming a 10 % market penetration. Our customers are healthcare institutions doing vascular interventions; the users of our product are vascular surgeons and interventional radiologists. Our total addressable market size in Europe and USA is around €300 M. Our goal is to revolutionize X-ray angiography by introducing a dose management and image processing tool. The current proposal is organized around the following objectives: a) clinical validation of our technology for new indications, b) organization of a reference laboratory network, c) software and hardware optimization to reach TRL 9 level and d) baseline commercial activities.
Campo scientifico
- natural sciencescomputer and information sciencessoftware
- natural sciencesbiological sciencescell biologycell metabolism
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- engineering and technologymedical engineeringdiagnostic imaging
- social scienceseconomics and businessbusiness and managementcommerce
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-SMEInst-2018-2020-3
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
2092 Budakeszi
Ungheria
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.